Trials / Completed
CompletedNCT00119652
Seroquel in Bipolar Depression Versus SSRI
Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 676 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | quetiapine fumarate (Seroquel) | |
| DRUG | paroxetine | |
| BEHAVIORAL | mood stabilizing activity |
Timeline
- Start date
- 2005-05-01
- Completion
- 2007-05-01
- First posted
- 2005-07-14
- Last updated
- 2013-01-04
Locations
55 sites across 11 countries: United States, Australia, Chile, Colombia, Costa Rica, Greece, Mexico, Peru, Romania, South Africa, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00119652. Inclusion in this directory is not an endorsement.